Sublingual Cannabidiol for Anxiety

• Status: Recruiting
• Trial end date: 2022-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label to double-blind study evaluating the effects of cannabidiol (CBD) for the treatment of anxiety in adults. Participants will use a sublingual (under-the-tongue) solution of whole plant-derived CBD or placebo three times daily for four weeks in addition to their normal treatment regimen. Participants' clinical state will be assessed weekly during the treatment period. In addition, cognitive function and measures of quality of life, sleep, and general health will be assessed at baseline and the post-treatment final visit.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Staci Gruber, Ph.D.
• Treatments: Cannabidiol

Criteria

Inclusion Criteria:

• 18 or older

• Native English speaker or acquired English prior to age 5

• Provides informed consent

• Endorses moderate or severe anxiety at the screening visit

Exclusion Criteria:

• Non-native English speakers

• Estimated IQ < 75

• Pregnancy

• Presence of serious medical illness, including liver or kidney disease, neurological disorder, or certain psychiatric disorders

• History of head injury or loss of consciousness >5 minutes

• Current use of cannabis or cannabinoid products >1x/month